I just took a look at the biopharmas in 4-Good Ventures portfolio. Nothing untoward happening in any of them. Aerami is going public through a SPAC and gaining $250 million to further development. Some of those biopharmas have drugs that will go head to head with Cytodyn and at a very quick glance will come off second best.